Advanced search
1 file | 821.99 KB

Poly(2-ethyl-2-oxazoline) as matrix excipient for drug formulation by hot melt extrusion and injection molding

Bart Claeys (UGent) , Anouk Vervaeck (UGent) , Chris Vervaet (UGent) , Jean Paul Remon (UGent) , Richard Hoogenboom (UGent) and Bruno De Geest (UGent)
(2012) MACROMOLECULAR RAPID COMMUNICATIONS. 33(19). p.1701-1707
Author
Organization
Abstract
Here we evaluate poly(2-ethyl-2-oxazoline)s (PEtOx) as a matrix excipient for the production of oral solid dosage forms by hot melt extrusion (HME) followed by injection molding (IM). Using metoprolol tartrate as a good water-soluble model drug we demonstrate that drug release can be delayed by HME/IM, with the release rate controlled by the molecular weight of the PEtOx. Using fenofibrate as a lipophilic model drug we demonstrate that relative to the pure drug the dissolution rate is strongly enhanced by formulation in HME/IM tablets. For both drug molecules we find that solid solutions, i.e. molecularly dissolved drug in a polymeric matrix, are obtained by HME/IM.
Keywords
solid solution, drug delivery, polyoxazolines, extrusion, pharmaceutics, DELIVERY, POLY(2-OXAZOLINE)S

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 821.99 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Claeys, Bart, Anouk Vervaeck, Chris Vervaet, Jean Paul Remon, Richard Hoogenboom, and Bruno De Geest. 2012. “Poly(2-ethyl-2-oxazoline) as Matrix Excipient for Drug Formulation by Hot Melt Extrusion and Injection Molding.” Macromolecular Rapid Communications 33 (19): 1701–1707.
APA
Claeys, Bart, Vervaeck, A., Vervaet, C., Remon, J. P., Hoogenboom, R., & De Geest, B. (2012). Poly(2-ethyl-2-oxazoline) as matrix excipient for drug formulation by hot melt extrusion and injection molding. MACROMOLECULAR RAPID COMMUNICATIONS, 33(19), 1701–1707.
Vancouver
1.
Claeys B, Vervaeck A, Vervaet C, Remon JP, Hoogenboom R, De Geest B. Poly(2-ethyl-2-oxazoline) as matrix excipient for drug formulation by hot melt extrusion and injection molding. MACROMOLECULAR RAPID COMMUNICATIONS. 2012;33(19):1701–7.
MLA
Claeys, Bart, Anouk Vervaeck, Chris Vervaet, et al. “Poly(2-ethyl-2-oxazoline) as Matrix Excipient for Drug Formulation by Hot Melt Extrusion and Injection Molding.” MACROMOLECULAR RAPID COMMUNICATIONS 33.19 (2012): 1701–1707. Print.
@article{3072339,
  abstract     = {Here we evaluate poly(2-ethyl-2-oxazoline)s (PEtOx) as a matrix excipient for the production of oral solid dosage forms by hot melt extrusion (HME) followed by injection molding (IM). Using metoprolol tartrate as a good water-soluble model drug we demonstrate that drug release can be delayed by HME/IM, with the release rate controlled by the molecular weight of the PEtOx. Using fenofibrate as a lipophilic model drug we demonstrate that relative to the pure drug the dissolution rate is strongly enhanced by formulation in HME/IM tablets. For both drug molecules we find that solid solutions, i.e. molecularly dissolved drug in a polymeric matrix, are obtained by HME/IM.},
  author       = {Claeys, Bart and Vervaeck, Anouk and Vervaet, Chris and Remon, Jean Paul and Hoogenboom, Richard and De Geest, Bruno},
  issn         = {1022-1336},
  journal      = {MACROMOLECULAR RAPID COMMUNICATIONS},
  language     = {eng},
  number       = {19},
  pages        = {1701--1707},
  title        = {Poly(2-ethyl-2-oxazoline) as matrix excipient for drug formulation by hot melt extrusion and injection molding},
  url          = {http://dx.doi.org/10.1002/marc.201200332},
  volume       = {33},
  year         = {2012},
}

Altmetric
View in Altmetric
Web of Science
Times cited: